Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. announced that its Chief Executive Officer, Dr. Neal Walker, along with other senior leadership, will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference. The event is scheduled for Thursday, June 4, 2026, at 2:00 PM ET, in New York, NY. A live and archived webcast of the fireside chat will be accessible on the company's website for at least 30 days.

Aclaris Therapeutics, Inc. announced that its President and Chief Operating Officer, Dr. Hugh Davis, will deliver a corporate presentation at the 2026 Bank of America Healthcare Conference. The presentation is scheduled for Thursday, May 14, 2026, at 9:35 AM PT in Las Vegas, NV. A live and archived webcast of the event will be accessible on the company's website for at least 30 days.

Aclaris Therapeutics reported an increased net loss of $(19.8) million for the first quarter of 2026, compared to $(15.1) million in the prior year, primarily due to higher research and development expenses. The company significantly strengthened its financial position by raising $57.9 million through an at-the-market common stock offering. As of March 31, 2026, Aclaris held $190.8 million in cash, cash equivalents, and marketable securities, which it believes is sufficient to fund operations for over 12 months.

Aclaris Therapeutics reported a net loss of $19.8 million for Q1 2026, compared to $15.1 million in Q1 2025, with total revenue increasing to $2.0 million. The company announced positive full top-line results from its Phase 1a trial of ATI-052, exceeding its target profile and showing potential for extended dosing. Aclaris also confirmed a strong cash position of $190.8 million, expected to fund operations through 2028, and provided updates on other pipeline candidates including planned Phase 2b trials for ATI-052 and ATI-2138.

Aclaris Therapeutics announced positive full top-line results from its Phase 1a SAD/MAD trial of ATI-052, an investigational bispecific antibody, confirming its potential for best-in-class potency and extended dosing up to every three months. The company also reported its first-quarter 2026 financial results, including a net loss of $19.8 million and total revenue of $2.0 million. Aclaris expects its cash, cash equivalents, and marketable securities of $190.8 million to fund operations through the end of 2028, supporting its pipeline development, including planned Phase 2b trials for ATI-052 and ATI-2138.

Aclaris Therapeutics announced positive full top-line results from its Phase 1a trial of ATI-052, an anti-TSLP/IL-4R bispecific antibody, demonstrating a potential best-in-class pharmacokinetic profile with an estimated half-life of 45 days, supporting up to three-month dosing. The trial showed robust target engagement and sustained inhibition of key inflammatory markers, with a favorable safety profile. Additionally, the company selected lichen planus as the lead indication for its selective ITK/JAK3 inhibitor ATI-2138, planning a Phase 2b basket study in H2 2026 for this unaddressed chronic inflammatory disease with a potential US market exceeding $1.0 billion.

Aclaris Therapeutics announced positive full results from its Phase 1a trial of ATI-052, an anti-TSLP/IL-4Rα bispecific antibody, showing a potential best-in-class pharmacokinetic profile with an estimated half-life of approximately 45 days, supporting up to three-month dosing. The trial demonstrated complete and sustained inhibition of TSLP-induced and IL-4 induced CCL17 (TARC) and a favorable safety profile. Additionally, the company selected lichen planus as the lead indication for its selective ITK/JAK3 inhibitor ATI-2138, with a Phase 2b basket study expected to begin in the second half of 2026. Enrollment is ongoing for Phase 1b trials of ATI-052 in asthma and atopic dermatitis, with top-line results expected in H2 2026.

Aclaris Therapeutics, Inc. announced it will release full results from its Phase 1a single and multiple ascending dose trial of its anti-TSLP/IL-4R bispecific antibody ATI-052 and the lead indication selection process for its ITK/JAK3 Inhibitor ATI-2138 on April 28, 2026, before market open. The company will host a webcast and conference call at 8:30 AM EST on the same day to discuss these updates. Aclaris is a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases.